Every material Form 8-K Steris filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
STERIS reported fiscal 2025 second-quarter results for the period ended September 30, 2024, with revenue from continuing operations up 7% to $1.3 billion and diluted EPS from continuing operations of $1.51, up from $1.20. The company reiterated its fiscal 2025 outlook, including adjusted EPS of $9.05 to $9.25, so shareholders see higher quarterly profit with no change to guidance.
Revenue rose 7% to $1.3 billion from $1.2 billion a year earlier.
Net income was $150.2 million, or $1.51 per diluted share, versus $119.8 million, or $1.20 per diluted share.
Adjusted EPS was $2.14, up from $1.86 in the prior-year quarter.
Fiscal 2025 adjusted EPS outlook of $9.05 to $9.25 was reiterated, and free cash flow for the first half was $344.5 million.
On October 7, 2024, STERIS and affiliated borrowers entered a $1.1 billion revolving credit agreement with JPMorgan Chase Bank as administrative agent, replacing the credit agreement dated March 19, 2021. The facility matures five years after October 7, 2024, and proceeds will fund general corporate purposes and working capital.
Revolving facility of $1,100 million, expandable by up to $625 million at lenders' discretion
Matures five years after October 7, 2024; interest is based on a base rate or relevant rate plus an applicable margin tied to STERIS's debt rating
Contains customary covenants, including limits on leverage and a minimum interest coverage requirement
Replaces the existing credit agreement dated March 19, 2021
STERIS reported fiscal 2025 first-quarter results for the period ended June 30, 2024. Revenue from continuing operations rose 8% to $1.3 billion, and reported diluted EPS from continuing operations increased to $1.41 from $1.31, while adjusted EPS rose to $2.03 from $1.84. The company reiterated its fiscal 2025 outlook, including adjusted EPS guidance of $9.05 to $9.25, but free cash flow fell to $195.7 million from $214.5 million.
Revenue from continuing operations increased 8% to $1.3 billion from $1.2 billion a year earlier; constant currency organic revenue grew 6%.
Reported diluted EPS from continuing operations was $1.41 versus $1.31; adjusted diluted EPS was $2.03 versus $1.84.
Fiscal 2025 adjusted EPS from continuing operations is expected at $9.05 to $9.25, compared with $8.20 in fiscal 2024.
Free cash flow was $195.7 million versus $214.5 million, which management attributed primarily to the timing of capital spending.
STERIS reported fiscal 2024 fourth-quarter revenue up 10% to $1.5 billion and full-year revenue up 12% to $5.5 billion, and announced a targeted restructuring plan with approximately $100 million in pre-tax charges. The fourth-quarter U.S. GAAP result was a net loss of $1.4 million, or $0.01 per diluted share, compared with net income of $187.2 million a year earlier, as results were negatively impacted by a $206.4 million pre-tax loss tied to the Dental segment and $44.4 million of restructuring charges. The company expects fiscal 2025 adjusted earnings per diluted share of $9.05 to $9.25, compared with $8.20 in fiscal 2024.
Q4 fiscal 2024 revenue rose 10% to $1.5 billion; Q4 U.S. GAAP net loss was $1.4 million, or $0.01 per diluted share, versus net income of $187.2 million a year earlier.
Full-year fiscal 2024 U.S. GAAP EPS was $3.81, up from $1.07; adjusted EPS was $8.83, up from $8.20.
Restructuring plan carries about $100 million in pre-tax charges, with $44.4 million recorded in Q4 and the balance in fiscal 2025; about $50 million is non-cash.
Fiscal 2025 outlook calls for revenue from continuing operations to rise 6.5% to 7.5% and adjusted EPS of $9.05 to $9.25.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Steris filing is on SEC EDGAR ↗. 8-K briefs of other companies →